Evidence map›Paper›PMID 30671209›Full record

ArticleMediterranean journal of hematology and infectious diseases2019

International Multicenter Experience in the Treatment Outcome of Invasive Aspergillosis in Immunocompromised Cancer Patients.

Ray Hachem, Marjorie V Batista, Souha S Kanj, Saeed El Zein, Sara Haddad, Ying Jiang, Nobuyoshi Mori, Rocha Vanderson, Anne-Marie Chaftari, Issam Raad

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mediterranean journal of hematology and infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 4 countries.

Ray HachemDepartment of Infectious Diseases, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Marjorie V BatistaHospital das Clinicas da Faculdade de Medicina de Sao Paulo, Sao Paulo, Brazil.
Souha S KanjDivision of Infectious Diseases, American University of Beirut Medical Center, Beirut, Lebanon.
Saeed El ZeinDivision of Infectious Diseases, American University of Beirut Medical Center, Beirut, Lebanon.
Sara HaddadDivision of Infectious Diseases, American University of Beirut Medical Center, Beirut, Lebanon.
Ying JiangDepartment of Infectious Diseases, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nobuyoshi MoriDivision of Infectious Diseases, St. Luke's International Hospital, Tokyo, Japan.
Rocha VandersonHospital das Clinicas da Faculdade de Medicina de Sao Paulo, Sao Paulo, Brazil.
Anne-Marie ChaftariInfection Control and Employee Health, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Issam RaadDepartment of Infectious Diseases, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USAmerican University of Beirut Medical Center · LBHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRSt. Luke's International Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInvasive aspergillosis (IA) is a life-threatening infection in immunocompromised patients. In this study, we compared the efficacy of voriconazole containing regimen vs non-voriconazole containing regimen in patients with IA.

methodsIn this retrospective study, we reviewed the medical records of all immunocompromised cancer patients diagnosed with proven or probable IA between February 2012 and March 2018. This trial included 26 patients from the American University of Beirut, Lebanon, 20 patients from Hospital das Clinicas da Faculdade de Medicina, Universidade de São Paulo, Brazil, and 10 patients from St. Luke's International Hospital Tokyo, Japan.

resultsA total of 56 patients were analyzed. They were divided into 2 groups voriconazole containing regimen and non-voriconazole containing regimen (90% Amphotericin B based regimen). Both groups had similar characteristic, age, gender, and immunocompromised status. The majority of patients had underlying leukemia (63%), followed by lymphoma (20%), myeloma (16%) and other hematologic malignancy (1%). Antifungal primary therapy with voriconazole-containing regimen was associated with better response to treatment (

conclusionsBased on international experience in immunocompromised cancer patients with IA, primary therapy with voriconazole-containing regimen is associated with improved response and survival compared with non-voriconazole amphotericin B based regimen.

Indexed as

ImmunocompromisedInvasive aspergillosisVoriconazole

Identifiers

PMID30671209
PMCPMC6328033
OpenAlexW2907383519

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.